AXL Inhibitors Clinical Trial Pipeline Insights Featuring 16+ Companies | DelveInsight

New York, USA, June 07, 2023 (GLOBE NEWSWIRE) — AXL Inhibitors Clinical Trial Pipeline Insights Featuring 16+ Companies | DelveInsight

The interest of Pharma and the research community in AXL inhibitors as anticancer agents has dramatically increased over the past years. The growing number of AXL inhibitors, and the ongoing clinical trials employing them, will allow the industry to determine the therapeutic potential of AXL targeting. AXL has emerged as a major therapeutic target and a potential biomarker in several cancer types, and future investigations are warranted to develop novel and effective treatment and diagnostic tools based on this target. Given the amount of evidence supporting the role of AXL in cancer and the increasing number of AXL-targeting candidates entering clinical trials, it is likely that such interest will continue to rise in the years to come.

DelveInsight’s ‘AXL Inhibitors Pipeline Insight 2023‘ report provides comprehensive global coverage of pipeline AXL inhibitors in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the AXL inhibitors pipeline domain.

Key Takeaways from the AXL Inhibitors Pipeline Report

• DelveInsight’s AXL inhibitors pipeline report depicts a robust space with 16+ active players working to develop 20+ pipeline AXL inhibitors. 
• Key AXL inhibitors companies such as Exelixis, BioAtla, Sumitomo Dainippon Pharma Oncology, Mirati Therapeutics, Aravive, Ono Pharmaceutical, BerGenBio, HEC Pharm, Exelixis, Betta Pharmaceuticals, and others are evaluating new AXL inhibitors drugs to improve the treatment landscape.
• Promising AXL inhibitors in the pipeline such as Batiraxcept, Cabozantinib, Sitravatinib, ONO-7475, Bemcentinib, BA3011, CT053, TP-0903, XL092, BPI-9016M, and others are under different phases of AXL inhibitors clinical trials.
• In May 2023, Aravive announced the presentation of updated results from its ongoing Phase 2 trial of batiraxcept in clear cell renal cell carcinoma (ccRCC) at the 2023 American Society of Clinical Oncology (ASCO) annual meeting, taking place June 2-6, 2023 in Chicago, IL and virtually. 
• In January 2022, BerGenBio ASA and Oslo University Hospital announced the execution of a collaborative agreement to study the BerGenBio AXL inhibitor bemcentinib, in hospitalized COVID-19 patients.
• In January 2022, BioAtla, Inc. entered into a clinical collaboration with Bristol Myers Squibb to investigate BioAtla’s two lead CAB-ADC candidates, BA3011 and BA3021, in combination with Bristol Myers Squibb’s anti-PD-1 therapy Opdivo (nivolumab). 

Request a sample and discover the recent advances in AXL inhibitors drugs @ AXL Inhibitors Pipeline Report

The AXL inhibitors pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage AXL inhibitors drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the AXL inhibitors clinical trial landscape.

AXL Inhibitors Overview

AXL is a TAM-related Receptor Tyrosine Kinase (RTK). It is a cell-surface transmembrane receptor that functions as a controlled kinase via its cytoplasmic domain. Mer and Tyro3 are also members of the TAM family. AXL is widely expressed in numerous organs, including macrophages, endothelial cells, the heart, liver, and skeletal muscle, where it serves a range of activities, including apoptosis clearance, cell survival regulation, vascular integrity maintenance, and hematopoiesis. AXL inhibitors have been demonstrated to increase tumor cell death while decreasing migration and invasion. Chemotherapy and other small-molecule inhibitors, such as VEGF, EGFR, PI3K, PARP, and HER2 inhibitors, are more effective when AXL is targeted. As a result, AXL inhibitors have the potential to be highly valuable at the center of cancer combination therapy, addressing largely unmet medical needs as well as several high-value market opportunities.

Find out more about AXL inhibitors @ AXL Inhibitors Drugs

A snapshot of the AXL Inhibitors Pipeline Drugs mentioned in the report:

Learn more about the emerging AXL inhibitors @ AXL Inhibitors Clinical Trials

AXL Inhibitors Therapeutics Assessment

The AXL inhibitors pipeline report proffers an integral view of the emerging novel AXL inhibitors segmented by stage, product type, molecule type, mechanism of action, and route of administration.

Scope of the AXL Inhibitors Pipeline Report 

• Coverage: Global 
• Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
• Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
• Therapeutics Assessment By Route of Administration: Intra-articular, Intraocular, Intrathecal, Intravenous, Oral, Parenteral, Subcutaneous, Topical, Transdermal
• Therapeutics Assessment By Molecule Type: Oligonucleotide, Peptide, Small molecule
• Key AXL Inhibitors Companies: Exelixis, BioAtla, Sumitomo Dainippon Pharma Oncology, Mirati Therapeutics, Aravive, Ono Pharmaceutical, BerGenBio, HEC Pharm, Exelixis, Betta Pharmaceuticals, and others
• Key AXL Inhibitors Pipeline Therapies: Batiraxcept, Cabozantinib, Sitravatinib, ONO-7475, Bemcentinib, BA3011, CT053, TP-0903, XL092, BPI-9016M, and others

Dive deep into rich insights for new AXL inhibitors, visit @ AXL Inhibitors in Pipeline

Table of Contents

For further information on the AXL inhibitors pipeline therapeutics, reach out @ AXL Inhibitors Analysis

Related Reports

Immune Checkpoint Inhibitors Competitive Landscape

Immune Checkpoint Inhibitors Competitive Landscape and Market Forecast – 2032 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key immune checkpoint inhibitors companies, including Regeneron, Bristol-Myers-Squibb, Novartis, GlaxoSmithKline, Merck, Roche, and AstraZeneca, among others.

Checkpoint Inhibitors Competitive Landscape

Checkpoint Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key checkpoint inhibitors companies, including BeiGene, Apollomics, BCN Biosciences, Phio Pharmaceuticals, Atridia, Jiangsu HengRui Medicine, EMD Serono, Innovent Biologics, Agenus, Eucure Biopharma, PharmaEngine, Vernalis, Array BioPharma, Genentech, Boehringer Ingelheim, Sentinel Oncology, Sierra Oncology, IMPACT Therapeutics, among others.

PD-1 Inhibitor Pipeline

PD-1 Inhibitor Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 inhibitor companies, including Genmab, RemeGen, Alphamab, OxSonics therapeutics, Light Chain Bioscience, ImmuneOnco Biopharma, Alpine Immune Sciences, Shanghai Henlius Biotech, Inc., Ocean Biomedical, Akeso Biopharma, Lyvgen Biopharma, Prestige Biopharma, ONO PHARMACEUTICAL CO., LTD., among others.

PD-1 and PD-L1 Inhibitors Competitive Landscape

PD-1 and PD-L1 Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key PD-1 and PD-L1 inhibitors companies, including Merck, Laekna Therapeutics, Genentech, Tracon Pharmaceuticals Inc., Celgene, MedImmune, Hangzhou Sumgen Biotech, Lepu Biopharma, Harbour BioMed, Curis, BeiGene, Apollomics, Agenus, Boehringer Ingelheim, Jounce Therapeutics, Seagen Inc., Ascletis Pharma Inc., Secarna Pharmaceuticals GmbH & Co. KG, Arbutus Biopharma, among others.

JAK Inhibitors Competitive Landscape

JAK Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key JAK inhibitors companies, including Pfizer, Sierra Oncology, Theravance Biopharma, Dizal Pharmaceutical, Aclaris Therapeutics, Celon Pharma, Incyte Corporation, AbbVie, Galapagos, among others.

TIGIT Inhibitors Competitive Landscape

TIGIT Inhibitors Competitive Landscape – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key TIGIT inhibitors companies, including Merck Sharp & Dohme, Bristol-Myers Squibb, BeiGene, Arcus Biosciences, iTeos Therapeutics, Mereo BioPharma, Phio Pharmaceuticals, Bio-Thera Solutions, Compugen, among others.

Other Trending Reports

Alopecia Market | Invasive Candidiasis Market | Bronchial Spasm Market | Chronic Gout Market | Hpv-Induced Cancers Market | Meningioma Market | Lewy Body Dementia Market | Anti-Gbm Disease Market | Colorectal Cancer CRC Market | Cervical Intraepithelial Neoplasia Market | Carpal Tunnel Syndrome Market | Nonalcoholic Steatohepatitis Market | AIDS Related Kaposis Sarcoma Market | Progressive Supranuclear Palsy Market | Tropical Spastic Paraparesis Market | Secondary Progressive Multiple Sclerosis SPMS Market | Systemic Sclerosis-Associated Interstitial Lung Disease Market | Reactive Airway Disease Market | Ptosis Market | AL Amyloidosis Market | Abdominal Aortic Aneurysm Market | X-Linked Retinitis Pigmentosa Market

Related Healthcare Blogs

Upcoming Oncological Drugs in 2023

Metastatic Castration-Sensitive Prostate Cancer Treatment Market

Checkpoint Inhibitor Refractory Cancer Market

Promising Oncolytic Virues Candidates in Pipeline

Cancer Biomarkers: Improving Treatment and Detection

Minimal Residual Disease (MRD) Testing: A Path to Cure Cancer?

ENHERTU’s Journey in Cancer Treatment and Management

Potential of PD-1 and PD-L1 Inhibitors in Cancer Management

Evolving EGFR NSCLC Treatment Market Dynamics

Emerging Role of Digital Health in the Field of Oncology

Related Cases Studies

Competitive Intelligence

Market Assessment

Product Assessment

Epidemiology Assessment

Related Healthcare Services

Healthcare Consulting

Healthcare Competitive Intelligence Services

Healthcare Asset Prioritization Services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. 

Connect with us at LinkedIn